Gut microbiome and anticancer immune response: Really hot Sh∗t!

Cell Death and Differentiation

Volumn 22, Issue 2, 2015, Pages 199-214

  Viaud, S ^a,b   Daillere R ^a,b   Boneca, I G ^a,c   Lepage, P ^d   Langella, P ^d   Chamaillard, M ^a,e,f,g   Pittet, M J ^h   Ghiringhelli, F ^a,i,j   Trinchieri, G ^k   Goldszmid, R ^k   Zitvogel, L ^a,b,l  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT PASTEUR   (France)

^d UMR1319 MICALIS   (France)

^e UNIV LILLE   (France)

^f INSERM U1019   (France)

^g CNRS   (France)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

^j UNIVERSITÉ DE BOURGOGNE   (France)

^k NATIONAL CANCER INSTITUTE   (United States)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ANIMAL; HUMAN; IMMUNOLOGY; INTESTINE; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA; MOUSE; NEOPLASM; PATHOLOGY; TH17 CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; INTESTINAL MUCOSA; INTESTINES; MICE; MICROBIOTA; NEOPLASMS; TH17 CELLS;

EID: 84900348675     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.56     Document Type: Review

References (135)

1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
2. Weinstock GM. Genomic approaches to studying the human microbiota. Nature 2012; 489: 250-256.
3. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
4. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326: 1694-1697.
5. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
6. Gophna U. Microbiology. The guts of dietary habits. Science 2011; 334: 45-46.
7. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108.
8. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107: 14691-14696.
9. Duarte R, Silva AM, Vieira LQ, Afonso LC, Nicoli JR. Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice. J Med Microbiol 2004; 53(Part 8): 741-748.
10. Neumann E, Oliveira MA, Cabral CM, Moura LN, Nicoli JR, Vieira EC et al. Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germfree mice. Braz J Med Biol Res 1998; 31: 1565-1573.
11. Souza DG, Vieira AT, Soares AC, Pinho V, Nicoli JR, Vieira LQ et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses. J Immunol 2004; 173: 4137-4146.
12. Oliveira MR, Tafuri WL, Afonso LC, Oliveira MA, Nicoli JR, Vieira EC et al. Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions. Parasitology 2005; 131(Part 4): 477-488.
13. van der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-v. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg 1971; 69: 405-411.
14. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848.
15. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920.
16. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 2007; 73: 1073-1078.
17. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
18. Collins J, Borojevic R, Verdu EF, Huizinga JD, Ratcliffe EM. Intestinal microbiota influence the early postnatal development of the enteric nervous system. Neurogastroenterol Motil 2014; 26: 98-107.
19. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med 2011; 3: 14.
20. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011; 9: 279-290.
21. Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013; 123: 700-711.
22. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101.
23. Mc CW, Mason JM III. Enterococcal endocarditis associated with carcinoma of the sigmoid; report of a case. J Med Assoc State of Alabama 1951; 21: 162-166.
24. Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis 2013; 13: 719-724.
25. Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 2002; 23: 529-536.
26. Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006; 313: 848-851.
27. Wu S, Rhee KJ, Zhang M, Franco A, Sears CL. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J Cell Sci 2007; 120Part 11: 1944-1952.
28. Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci USA 2011; 108: 15354-15359.
29. Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci USA 2012; 109: E1820-E1829.
30. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.
31. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
32. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-298.
33. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A et al. Towards the human colorectal cancer microbiome. PLoS One 2011; 6: e20447.
34. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393.
35. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-582.
36. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15: 1016-1022.
37. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
38. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-258.
39. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-323.
40. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 2012; 149: 1578-1593.
41. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010; 107: 12204-12209.
42. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-341.
43. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498.
44. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31: 677-689.
45. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-455.
46. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815-827.
47. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008; 455: 1109-1113.
48. van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathogen 2010; 6: e1000879.
49. Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10: 79-83.
50. Ijiri K, Potten CS. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 1987; 55: 113-123.
51. Dekaney CM, Gulati AS, Garrison AP, Helmrath MA, Henning SJ. Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice. Am J Physiol Gastrointest Liver Physiol 2009; 297: G461-G470.
52. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 2008; 7: 1919-1925.
53. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725.
54. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757.
55. Manhart N, Vierlinger K, Spittler A, Bergmeister H, Sautner T, Roth E. Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer's patches in endotoxemic mice. Ann Surg 2001; 234: 92-97.
56. Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 1999; 35: 202-207.
57. Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One 2012; 7: e39764.
58. Maruya M, Kawamoto S, Kato LM, Fagarasan S. Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency. Gut Microbes 2013; 4: 165-171.
59. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 2012; 336: 485-489.
60. Rossini A, Rumio C, Sfondrini L, Tagliabue E, Morelli D, Miceli R et al. Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res 2006; 66: 6219-6224.
61. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA 2004; 291: 827-835.
62. Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature 2011; 476: 393-394.
63. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013; 104: 22-27.
64. LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells - targets for cancer immunotherapy. Nat Rev Urol 2013; 10: 537-545.
65. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G et al. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2: e25238.
66. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991; 9: 1151-1156.
67. Tsuda K, Yamanaka K, Linan W, Miyahara Y, Akeda T, Nakanishi T et al. Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses. PLoS One 2011; 6: e29020.
68. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ et al. Activation of tolllike receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541.
69. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-4417.
70. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976.
71. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970.
72. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369-383.
73. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71: 661-665.
74. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-549.
75. Hand TW, Dos Santos LM, Bouladoux N, Molloy MJ, Pagan AJ, Pepper M et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 2012; 337: 1553-1556.
76. Cong Y, Feng T, Fujihashi K, Schoeb TR, Elson CO. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA 2009; 106: 19256-19261.
77. Farago AF, Snyder EL, Jacks T. SnapShot: lung cancer models. Cell 2012; 149: 246-246 e241.
78. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 2012; 109: 2491-2496.
79. Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013; 38: 296-308.
80. Alegre ML, Bartman C, Chong AS. Microbes and allogeneic transplantation. Transplantation 2014; 97: 5-11.
81. Chong AS, Alegre ML. The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol 2012; 12: 459-471.
82. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70: 490-500.
83. Faye T, Tamburello A, Vegarud GE, Skeie S. Survival of lactic acid bacteria from fermented milks in an in vitro digestion model exploiting sequential incubation in human gastric and duodenum juice. J Dairy Sci 2012; 95: 558-566.
84. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827-833.
85. Miyauchi E, Morita H, Okuda J, Sashihara T, Shimizu M, Tanabe S. Cell wall fraction of Enterococcus hirae ameliorates TNF-alpha-induced barrier impairment in the human epithelial tight junction. Lett Appl Microbiol 2008; 46: 469-476.
86. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
87. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathogen 2012; 8: e1002995.
88. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953.
89. Kolars JC, Levitt MD, Aouji M, Savaiano DA. Yogurt-an autodigesting source of lactose. N Engl J Med 1984; 310: 1-3.
90. Khazaie K, Zadeh M, Khan MW, Bere P, Gounari F, Dennis K et al. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA 2012; 109: 10462-10467.
91. Motta JP, Bermudez-Humaran LG, Deraison C, Martin L, Rolland C, Rousset P et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4: 158ra144.
92. Carroll IM, Andrus JM, Bruno-Barcena JM, Klaenhammer TR, Hassan HM, Threadgill DS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G729-G738.
93. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 2009; 20: 743-752.
94. Lampe JW. Emerging research on equol and cancer. J Nutr 2010; 140: 1369S-1372S.
95. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Alim Pharmacol Therap 2008; 27: 104-119.
96. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573.
97. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557-561.
98. Steinbrecher KA, Harmel-Laws E, Sitcheran R, Baldwin AS. Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol 2008; 180: 2588-2599.
99. Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010; 207: 1513-1523.
100. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206: 1465-1472.
101. Kajino-Sakamoto R, Inagaki M, Lippert E, Akira S, Robine S, Matsumoto K et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol 2008; 181: 1143-1152.
102. Kim JY, Kajino-Sakamoto R, Omori E, Jobin C, Ninomiya-Tsuji J. Intestinal epithelialderived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. PLoS One 2009; 4: e4561.
103. Welz PS, Wullaert A, Vlantis K, Kondylis V, Fernandez-Majada V, Ermolaeva M et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330-334.
104. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335-339.
105. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134: 743-756.
106. Adolph TE, Tomczak MF, Niederreiter L, Ko HJ, Bock J, Martinez-Naves E et al. Paneth cells as a site of origin for intestinal inflammation. Nature 2013; 503: 272-276.
107. Coulombe G, Leblanc C, Cagnol S, Maloum F, Lemieux E, Perreault N et al. Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Mol Cell Biol 2013; 33: 2275-2284.
108. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129.
109. Burger-van Paassen N, van der Sluis M, Bouma J, Korteland-van Male AM, Lu P, Van Seuningen I et al. Colitis development during the suckling-weaning transition in mucin Muc2-deficient mice. Am J Physiol Gastrointest Liver Physiol 2011; 301: G667-G678.
110. Harmel-Laws E, Mann EA, Cohen MB, Steinbrecher KA. Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis. PLoS One 2013; 8: e79180.
111. Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest 2013; 123: 3983-3996.
112. Chen GY, Liu M, Wang F, Bertin J, Nunez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186: 7187-7194.
113. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
114. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial selfrenewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108: 9601-9606.
115. Gong J, Xu J, Zhu W, Gao X, Li N, Li J. Epithelial-specific blockade of MyD88-dependent pathway causes spontaneous small intestinal inflammation. Clin Immunol 2010; 136: 245-256.
116. Frantz AL, Rogier EW, Weber CR, Shen L, Cohen DA, Fenton LA et al. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides. Mucosal Immunol 2012; 5: 501-512.
117. Hoshi N, Schenten D, Nish SA, Walther Z, Gagliani N, Flavell RA et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat Commun 2012; 3: 1120.
118. Turgeon N, Blais M, Gagne JM, Tardif V, Boudreau F, Perreault N et al. HDAC1 and HDAC2 restrain the intestinal inflammatory response by regulating intestinal epithelial cell differentiation. PLoS One 2013; 8: e73785.
119. Alenghat T, Osborne LC, Saenz SA, Kobuley D, Ziegler CG, Mullican SE et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature 2013; 504: 153-157.
120. Dalmasso G, Nguyen HT, Ingersoll SA, Ayyadurai S, Laroui H, Charania MA et al. The PepT1-NOD2 signaling pathway aggravates induced colitis in mice. Gastroenterology 2011; 141: 1334-1345.
121. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007; 131: 33-45.
122. Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 2010; 8: 292-300.
123. Kühn R, Lohler J, Rennick D, Rajewsky K, MullerW. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
124. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006; 25: 319-329.
125. Gomes-Santos AC, Moreira TG, Castro-Junior AB, Horta BC, Lemos L, Cruz DN et al. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol 2012; 2012: 560817.
126. Yoshihara K, Yajima T, Kubo C, Yoshikai Y. Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut 2006; 55: 334-341.
127. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-957.
128. Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 2013; 190: 5306-5312.
129. Takamatsu M, Hirata A, Ohtaki H, Hoshi M, Hatano Y, Tomita H et al. IDO1 plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. J Immunol 2013; 191: 3057-3064.
130. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003; 125: 1762-1773.
131. Nguyen DD, Maillard MH, Cotta-de-Almeida V, Mizoguchi E, Klein C, Fuss I et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology 2007; 133: 1188-1197.
132. Nguyen DD, Wurbel MA, Goettel JA, Eston MA, Ahmed OS, Marin R et al. Wiskott-Aldrich syndrome protein deficiency in innate immune cells leads to mucosal immune dysregulation and colitis in mice. Gastroenterology 2012; 143: 719-729 e711-712.
133. Brenner O, Levanon D, Negreanu V, Golubkov O, Fainaru O, Woolf E et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA 2004; 101: 16016-16021.
134. Furumatsu K, Nishiumi S, Kawano Y, Ooi M, Yoshie T, Shiomi Y et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci 2011; 56: 2532-2544.
135. Qiao G, Yang L, Li Z, Ying H, Hassen Y, Yin F et al. Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism. Clin Immunol 2012; 143: 128-133.